Kazia CEO John Friend to Attend JPM Week, Advancing Breast Cancer Research
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Source: Newsfilter
- Strategic Conference Participation: Kazia Therapeutics CEO John Friend will attend the J.P. Morgan Healthcare Conference next week in San Francisco to connect with existing and prospective investors and strategic partners, thereby enhancing the company's investor relations and business development efforts.
- Post-Financing Momentum: Following a successful financing round, Kazia is well-capitalized to execute on multiple near-term catalysts, including an anticipated clinical and biomarker update for triple-negative breast cancer (TNBC) by the end of the month, which will enhance the company's competitiveness in oncology.
- Clinical Update Expectations: Kazia expects to provide an update on its ongoing Phase 1b trial for TNBC by the end of January, potentially including expanded analyses of circulating tumor cells (CTCs) and CTC clusters, thereby supporting paxalisib's potential impact on metastatic disease biology with more clinical data.
- New Drug Development Progress: Kazia plans to provide the first update on its potential first-in-class PD-L1 protein degrader program, aimed at leveraging a novel mechanism to address challenges in immune-based cancer therapies, further advancing the company's innovative capabilities in cancer treatment.
Analyst Views on KZIA
Wall Street analysts forecast KZIA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KZIA is 19.00 USD with a low forecast of 18.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.930
Low
18.00
Averages
19.00
High
20.00
Current: 7.930
Low
18.00
Averages
19.00
High
20.00
About KZIA
Kazia Therapeutics Limited is an Australia-based pharmaceutical drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
